FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Home
/
update
/
details

Myriad Genetics and Ultima Genomics Partner to Revolutionize Genetic Testing with UG 100 Sequencing Platform

NextEdge Admin

05 Oct 2024

2 min 17 sec

Myriad Genetics, a leader in genetic testing and precision medicine, and Ultima Genomics, known for its revolutionary ultra-high throughput next-generation sequencing (NGS) platform, announced a collaboration to explore Ultima’s UG 100™ sequencing platform and ppmSeq™ technology. Myriad has acquired a UG 100 for its new Lab of the Future in South San Francisco, where it will be used to advance clinical testing.

The UG 100’s low-cost, high-fidelity sequencing capabilities could enhance several of Myriad's emerging products. One of these is the Precise Molecular Residual Disease (MRD) test, which uses whole-genome sequencing on tumor and normal tissue samples to identify tumor-specific variants for personalized tracking. With the support of Ultima’s technology, Myriad aims to improve the test’s performance and cost efficiency.

In reproductive health, Myriad is preparing to launch FirstGene, a multiple prenatal screen that runs the content of various tests in a single sequencing workflow. The UG 100's deep and accurate sequencing may help provide cost-effective results for FirstGene.

Sam Raha, Chief Operating Officer of Myriad Genetics, expressed excitement about the potential of the UG 100 to lower costs, improve quality, and deepen insights. Gilad Almogy, CEO of Ultima Genomics, noted that their ppmSeq technology offers exceptional accuracy, especially for oncology applications like MRD, and can transform testing methods with its low-cost, whole-genome sequencing. Both companies are optimistic about the future impact of this partnership on precision medicine.